Log in to save to my catalogue

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1641449742

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

About this item

Full title

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2015-01, Vol.372 (1), p.30-39

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In patients with melanomas containing activating
BRAF
mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared with a BRAF inhibitor alone, and was associated with many fewer second skin tumors.
The treatment of metastatic melanoma is rapidly evolving. The potent and specific BRAF inhibitors...

Alternative Titles

Full title

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1641449742

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1641449742

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1412690

How to access this item